Human Amniotic Fluid

Phase 2Biologic

UUniversity of Utah

Human Amniotic Fluid is one of 68 biologic programs targeting Respiratory Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory FailureActive, not recruiting

COVID-19Active, not recruiting

Venous Stasis UlcerRecruiting

Respiratory FailurePhase 1

Active, not recruiting

COVID-19Phase 1/Phase 2

Active, not recruiting

Venous Stasis UlcerPhase 2

Recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Bnt162b2

BioNTech

Preclinical

29 3

Human Amniotic Fluid

UUniversity of Utah

Phase 2

1 4

Glucocorticoid

AbbVie

Preclinical

1 5

Nadroparin

GSK

Preclinical

1 6

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 7

Calcium

Aprotinin

1 9

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 10

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Venous Stasis Ulcer

NCT04647240

Clinical

Trials by Indication[1]

COVID-191 trial

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

Completed·UUniversity of Utah·Phase 1/2·NCT04497389·47 enrolled

Respiratory Failure1 trial

A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure

Completed·UUniversity of Utah·Phase 1·NCT04319731·10 enrolled

Venous Stasis Ulcer1 trial

A Two Part, Randomized Study of MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers

Recruiting·MMerakris Therapeutics·Phase 2·NCT04647240·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Human Amniotic Fluid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human Amniotic Fluid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human Amniotic Fluid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Utah company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Utah

Human Amniotic Fluid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

COVID-191 trial

Respiratory Failure1 trial

Venous Stasis Ulcer1 trial

References

Drug Info

Quick Facts

Related News